VR Ultrasound Guided Breast Localization

Sponsor
Prisma Health-Upstate (Other)
Overall Status
Completed
CT.gov ID
NCT04251507
Collaborator
Clemson University (Other)
60
1
2
11.8
5.1

Study Details

Study Description

Brief Summary

To determine if a virtual reality simulation will reduce pain and anxiety in patients undergoing an ultrasound guided breast localization procedure (traditional wire, savi scout or a radiofrequency identification tag).

Condition or Disease Intervention/Treatment Phase
  • Device: Oculus Go Virtual Reality Goggles
N/A

Detailed Description

Needle localizations for breast cancer surgery are required to identify cancerous tissue before surgery. Currently this procedure is done with or without a local anesthetic. Patients report anxiety regarding cancer and cancer-related procedures. Different types of needle localization may have different pain and anxiety based on their duration, complexity, and invasiveness. This research is designed to determine if VR simulated environment can reduce pain and anxiety.

Our aim is to study the efficacy of a virtual environment in reducing pain and procedural anxiety. It is intended for patients undergoing an ultrasound guided breast localization procedure that have had an abnormal breast biopsy. The overall aim is to discover an efficacious nonpharmacologic method to lower pain and anxiety during a standard of care procedure.

Study Design

Study Type:
Interventional
Actual Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
The Use of Virtual Reality During Breast Localization Procedures
Actual Study Start Date :
Jan 13, 2021
Actual Primary Completion Date :
Jan 7, 2022
Actual Study Completion Date :
Jan 7, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Virtual Reality Goggles

Patients randomized to the intervention group will undergo their procedure as standard of care but will wear the Oculus Go Goggles and experience a virtual reality simulation. The simulation is a non-interactive polar theme video.

Device: Oculus Go Virtual Reality Goggles
Oculus Go is a standalone portable Virtual Reality device that enables the user to immerse in different virtual environments.Non pharmacological technique to reduce pain and anxiety during a procedure.

No Intervention: Control

Patients randomized to the control group will undergo their procedure as standard of care without the use of virtual reality goggles.

Outcome Measures

Primary Outcome Measures

  1. Subjective Pain Assessment: Visual Analog Scale [Immediate post-procedure]

    Pain Measured with the Visual Analog Scale. Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured. The individual will score their pain level by circling a number 0 - 10 at baseline, pre-operative, and post-operatively. The scale range includes 0-10 scales, with < 2 =well controlled, 2 - 5: partly controlled, > 5: uncontrolled.

Secondary Outcome Measures

  1. State-Trait Anxiety Inventory (STAI: Y-6 item) [Immediate post-procedure]

    The State-Trait Anxiety Inventory uses a 4 point Likert scale to assess how much worry, tension or apprehension the subject experiences in his or her present circumstances (state anxiety) and how much anxiety represent a personality characteristic (trait anxiety). Items emphasize the frequency of particular symptoms (ranging from 1 = not at all to 4 = very much). The range of possible scores for form Y of the STAI varies from a minimum score of 20 to a maximum score of 80 on both the STAI-T and STAI-S subscales. STAI scores are commonly classified as "no or low anxiety" (20-37), "moderate anxiety" (38-44), and "high anxiety" (45-80).

  2. Patient Satisfaction [Immediate post-procedure]

    Patients in both groups will be asked to rate their satisfaction with their procedures using a five point likert scale (ranging from 1 = definitely disagree to 5 = definitely agree).

Other Outcome Measures

  1. Heart Rate [Immediate post-procedure]

    Empatica E4 watch is a wearable device that collects real-time physiological data. This wristband is equipped with photoplethysmogram sensors for computing Heart Rate (HR). Heart rate will be reported in beats per minute (bpm).

  2. Temperature [Immediate post-procedure]

    Empatica E4 watch is a wearable device that collects real-time physiological data. The photoplethysmogram sensor from the watch will measure temperature. Temperature will be reported in degrees Celsius.

  3. Blood Volume Pulse Signal [Immediate post-procedure]

    Empatica E4 watch is a wearable device that collects real-time physiological data. The photoplethysmogram sensor from the watch will measure variation of volume of arterial blood under the skin resulting from the heart cycle computing Blood Volume Pulse (BVP). Blood Volume Pulse will be measured in beats min-1.

  4. Galvanic Skin Response [Immediate post-procedure]

    The Empatica E4 watch is a wearable device that collects real-time physiological data. The photoplethysmogram skin electrodes from the watch will capture the Galvanic Skin Response (GSR), also named Electrodermal Activity (EDA) and Skin Conductance (SC) or the measure of the continuous variations in the electrical characteristics of the skin. GSR will be reported in units of micro-Siemens (μS).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Informed consent is obtained from the patient

  • Females ≥ 18 years of age

  • Patient is schedule for preoperative ultrasound guided breast localization procedure

Exclusion Criteria:
  • Patient is scheduled for or switched to a stereotactic localization procedure

  • The patient has motion sickness

  • The patient has severe cognitive disabilities or language barriers that inhibit study form completion in English

  • Refusal of patient to sign consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Prisma Health Greenville South Carolina United States 29615

Sponsors and Collaborators

  • Prisma Health-Upstate
  • Clemson University

Investigators

  • Principal Investigator: Andrea Nisonson, MD, Prisma Health-Upstate

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Prisma Health-Upstate
ClinicalTrials.gov Identifier:
NCT04251507
Other Study ID Numbers:
  • Pro00092817
First Posted:
Feb 5, 2020
Last Update Posted:
Apr 19, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Prisma Health-Upstate
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 19, 2022